Tag Archives: Pomalyst

Darzalex for Refractory Multiple Myeloma

Darzalex (daratumumab), and anti-CD38 monoclonal antibody for the treatment of patients with multiple myeloma who had already undergone at least three prior standard treatments, received FDA approval. The product was developed by J&J and Genmab. Continue reading